Misplaced Pages

Loperamide: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 12:34, 3 March 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid) per Chem/Drugbox validation (report errors or bugs)← Previous edit Latest revision as of 08:17, 22 December 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits rank 
(741 intermediate revisions by more than 100 users not shown)
Line 1: Line 1:
{{Short description|Medicine used to reduce diarrhea}}
{{Redirect|Imodium|the ] song once called "Imodium"|Breed (song)}}
{{Use dmy dates|date=January 2024}}
{{drugbox
{{cs1 config |name-list-style=vanc |display-authors=6}}
| verifiedrevid = 411037005
{{Infobox drug
| IUPAC_name = 4-- ''N,N''-dimethyl-2,2-diphenylbutanamide
| Verifiedfields = changed
| image = Loperamide.svg
| Watchedfields = changed
| image2 = Loperamide2mg.JPG
| verifiedrevid = 416898838
| CASNo_Ref = {{cascite|correct|CAS}}
| image = Loperamide.svg
| width = 250
| alt =
| image2 = Loperamide 3D ball.png
| width2 = 235
| alt2 =
| USAN = Loperamide hydrochloride

<!-- Clinical data -->
| pronounce = {{IPAc-en|l|oʊ|ˈ|p|ɛr|ə|m|aɪ|d}}
| tradename = Imodium, others<ref name=Names/>
| Drugs.com = {{drugs.com|monograph|loperamide-hydrochloride}}
| MedlinePlus = a682280
| DailyMedID = Loperamide
| pregnancy_AU = B3
| routes_of_administration = ]
| ATC_prefix = A07
| ATC_suffix = DA03
| ATC_supplemental = <br />{{ATC|A07|DA05}} (oxide)

| legal_AU = S2
| legal_BR = C1
| legal_BR_comment = <ref>{{cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=31 March 2023 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=3 August 2023 |access-date=16 August 2023 |publisher=] |language=pt-BR |publication-date=4 April 2023}}</ref>
| legal_CA = OTC
| legal_UK = GSL
| legal_US = OTC
| legal_US_comment = /&nbsp;Rx-only<ref>{{cite web | title=Loperamide hydrochloride capsule | website=DailyMed | date=30 September 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f | access-date=8 January 2024 | archive-date=14 September 2023 | archive-url=https://web.archive.org/web/20230914040736/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f | url-status=live }}</ref>

<!-- Pharmacokinetic data -->
| bioavailability = 0.3%
| protein_bound = 97%
| metabolism = ] (extensive)
| elimination_half-life = 9–14 hours<ref name=AHFS2015/>
| excretion = Feces (30–40%), urine (1%)

<!-- Identifiers -->
| IUPHAR_ligand = 7215
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 53179-11-6
| PubChem = 3955
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00836
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3818
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6X9OC3H4II | UNII = 6X9OC3H4II
| KEGG_Ref = {{keggcite|correct|kegg}}
| InChI = 1/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
| KEGG = D08144
| InChIKey = RDOIQAHITMMDAJ-UHFFFAOYAJ
| ChEBI_Ref = {{ebicite|changed|EBI}}
| smiles = Clc1ccc(cc1)C4(O)CCN(CCC(c2ccccc2)(c3ccccc3)C(=O)N(C)C)CC4
| ChEBI = 6532
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 841 | ChEMBL = 841
| synonyms = R-18553

<!-- Chemical data -->
| IUPAC_name = 4--''N,N''-dimethyl-2,2-diphenylbutanamide
| C=29 | H=33 | Cl=1 | N=2 | O=2
| SMILES = ClC1=CC=C(C2(CCN(CC2)CCC(C3=CC=CC=C3)(C(N(C)C)=O)C4=CC=CC=C4)O)C=C1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3 | StdInChI = 1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RDOIQAHITMMDAJ-UHFFFAOYSA-N | StdInChIKey = RDOIQAHITMMDAJ-UHFFFAOYSA-N
| CAS_number = 53179-11-6
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3818
| CAS_supplemental = (with HCl)
| ATC_prefix = A07
| ATC_suffix = DA03
| ATC_supplemental = {{ATC|A07|DA05}}
| PubChem = 3955
| smiles Clc1ccc(cc1)C1(O)CCN(CCC(c2ccccc2)(c2ccccc2)C(=O)N(C)C)CC1
| DrugBank = APRD00275
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08144
| C=29 | H=33 | Cl=1 | N=2 | O=2
| molecular_weight = 477.037 g/mol (513.506 with HCl)
| bioavailability = Not significantly absorbed from the gut
| protein_bound = 97%
| metabolism = ]
| elimination_half-life = 9.1 to 14.4 hours (average 10.8 hours)
| excretion =
| pregnancy_category = B<ref>"." ''DailyMed''.</ref>
| legal_US = OTC
| legal_CA = (OTC)
| legal_UK = GSL
| routes_of_administration = oral, insufflation
}} }}
<!-- Definition and medical uses -->
'''Loperamide''', sold under the brand name '''Imodium''', among others,<ref name=Names>Drugs.com {{webarchive|url=https://web.archive.org/web/20150923230214/http://www.drugs.com/international/loperamide.html |date=23 September 2015 }} Page accessed 4 September 2015</ref> is a ] of the ] class used to decrease the frequency of ].<ref name="auto">{{Cite web|url=https://www.nhs.uk/medicines/loperamide/about-loperamide/|title=About loperamide|date=11 April 2024|website=nhs.uk}}</ref><ref name=AHFS2015>{{cite web|title=Loperamide Hydrochloride|url=https://www.drugs.com/monograph/loperamide-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|access-date=25 August 2015|url-status=live|archive-url=https://web.archive.org/web/20150907231103/http://www.drugs.com/monograph/loperamide-hydrochloride.html|archive-date=7 September 2015}}</ref> It is often used for this purpose in ], ], ],<ref name=AHFS2015/> ], and ].<ref name="auto"/> It is not recommended for those with ], mucus in the stool, or ].<ref name=AHFS2015/> The medication is ].<ref name=AHFS2015/>


<!-- Side effects -->
'''Loperamide''' ({{pron-en|loʊˈpɛrəmaɪd}}), a synthetic ] derivative,<ref></ref> is an opioid ] effective against ] resulting from ] or ]. In most countries it is available generically and under brand names such as '''Lopex''', '''Imodium''', '''Dimor''', '''Fortasec''' and '''Pepto''' Diarrhea Control. It was developed at ].{{Citation needed|date=May 2010}}
Common side effects include ], ], ], ], and ].<ref name=AHFS2015/> It may increase the risk of ].<ref name=AHFS2015/> Loperamide's safety in ] is unclear, but no evidence of harm has been found.<ref name=AG2015>{{cite web|title=Prescribing medicines in pregnancy database|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm|work=Australian Government|access-date=22 April 2014|date=3 March 2014|url-status=live|archive-url=https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm |archive-date=8 April 2014}}</ref> It appears to be safe in ].<ref>{{cite web|title=Loperamide use while Breastfeeding|url=https://www.drugs.com/breastfeeding/loperamide.html|access-date=26 August 2015|url-status=live|archive-url=https://web.archive.org/web/20150908034709/http://www.drugs.com/breastfeeding/loperamide.html|archive-date=8 September 2015}}</ref> It is an ] with no significant absorption from the gut and does not cross the ] when used at normal doses.<ref name=NCI2015Dic>{{cite web|title=loperamide hydrochloride|url=http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=41911|website=NCI Drug Dictionary|access-date=26 August 2015|url-status=live|archive-url=https://web.archive.org/web/20150907211727/http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=41911|archive-date=7 September 2015|date=2 February 2011}}</ref> It works by slowing the contractions of the ].<ref name=AHFS2015/>

<!-- History, society, and culture -->
Loperamide was first made in 1969 and used medically in 1976.<ref name="Oxford University Press">{{cite book|vauthors=Patrick GL|title=An introduction to medicinal chemistry|date=2013|publisher=Oxford University Press|location=Oxford|isbn=9780199697397|pages=644|edition=Fifth|url=https://books.google.com/books?id=Pj7xJRuhZxUC&pg=PA644|access-date=17 December 2020|archive-date=14 January 2023|archive-url=https://web.archive.org/web/20230114195405/https://books.google.com/books?id=Pj7xJRuhZxUC&pg=PA644|url-status=live}}</ref> It is on the ].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> Loperamide is available as a ].<ref name=AHFS2015/><ref name=Ric2013>{{cite book| vauthors = Hamilton RJ |title=Tarascon pocket pharmacopoeia|date=2013|publisher=Jones & Bartlett Learning|location=|isbn=9781449673611|pages = 217|edition=14|url=https://books.google.com/books?id=zJay-fZCFGgC&pg=PA217|url-status=live|archive-url=https://web.archive.org/web/20160305005322/https://books.google.com/books?id=zJay-fZCFGgC&pg=PA217|archive-date=5 March 2016}}</ref> In 2022, it was the 297th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.<ref name="Top 300 of 2022">{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Loperamide Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Loperamide | access-date = 30 August 2024 }}</ref>

==Medical uses==
Loperamide is effective for the treatment of a number of types of diarrhea.<ref>{{cite journal | vauthors = Hanauer SB | title = The role of loperamide in gastrointestinal disorders | journal = Reviews in Gastroenterological Disorders | volume = 8 | issue = 1 | pages = 15–20 | date =Winter 2008 | pmid = 18477966 }}</ref> This includes control of acute nonspecific diarrhea, mild ], irritable bowel syndrome, chronic diarrhea due to bowel resection, and chronic diarrhea secondary to inflammatory bowel disease. It is also useful for reducing ] output. ]s for loperamide also include chemotherapy-induced diarrhea, especially related to ] use.

Loperamide should not be used as the primary treatment in cases of ], acute exacerbation of ], or bacterial ].<ref name=drugs.com>{{cite web|url=https://www.drugs.com/pro/loperamide.html|title=Loperamide|access-date=14 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160520143952/http://www.drugs.com/pro/loperamide.html|archive-date=20 May 2016}}</ref>

Loperamide is often compared to ]. Studies suggest that loperamide is more effective and has lower neural side effects.<ref>{{cite book| vauthors = Miftahof R |date=2009 |title=Mathematical Modeling and Simulation in Enteric Neurobiology |url= https://books.google.com/books?id=3Qyd9TmOY5EC&pg=PA18 |publisher=World Scientific |isbn=9789812834812 |pages = 18|url-status=live |archive-url=https://web.archive.org/web/20170728102724/https://books.google.com/books?id=3Qyd9TmOY5EC&pg=PA18&dq=|archive-date=28 July 2017}}</ref><ref>{{cite book| veditors = Benson A, Chakravarthy A, Hamilton SR, Elin S |date=2013|title=Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management |url= https://books.google.com/books?id=afb1AAAAQBAJ&q=D&pg=PA225 |publisher=Demos Medical Publishing|isbn=9781936287581 |pages = 225|url-status=live |archive-url= https://web.archive.org/web/20170908145128/https://books.google.com/books?id=afb1AAAAQBAJ&pg=PA225&dq=D#v=onepage&q=D&f=false|archive-date=8 September 2017}}</ref><ref>{{cite book| vauthors = Zuckerman JN |date=2012|title=Principles and Practice of Travel Medicine|url=https://books.google.com/books?id=FXxksru7IQYC&pg=PA203|publisher=John Wiley & Sons|isbn=9781118392089|pages = 203|url-status=live|archive-url=https://web.archive.org/web/20170908145128/https://books.google.com/books?id=FXxksru7IQYC&pg=PA203&dq=|archive-date=8 September 2017}}</ref>

==Side effects==
]s most commonly associated with loperamide are constipation (which occurs in 1.7–5.3% of users), dizziness (up to 1.4%), nausea (0.7–3.2%), and abdominal cramps (0.5–3.0%).<ref name=ReferenceA>{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/017694s050lbl.pdf |title=Imodium label |publisher=U.S. ] (FDA) |access-date=21 April 2014 |url-status=live |archive-url=https://web.archive.org/web/20140423055633/http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/017694s050lbl.pdf |archive-date=23 April 2014 }}</ref> Rare, but more serious, side effects include toxic megacolon, ], ], anaphylaxis/allergic reactions, ], ], ], ], and ].<ref>{{cite web|url=https://online.epocrates.com/noFrame/showPage.do;jsessionid=FB4C4C42205138677A3F9E475E6C6299?method=drugs&MonographId=44&ActiveSectionId=5|title=loperamide adverse reactions|access-date=14 May 2016|archive-url=https://web.archive.org/web/20181101071123/https://online.epocrates.com/noFrame/showPage.do;jsessionid=FB4C4C42205138677A3F9E475E6C6299?method=drugs&MonographId=44&ActiveSectionId=5|archive-date=1 November 2018|url-status=dead}}</ref> The most frequent symptoms of loperamide overdose are drowsiness, vomiting, and abdominal pain, or burning.<ref>{{cite journal | vauthors = Litovitz T, Clancy C, Korberly B, Temple AR, Mann KV | title = Surveillance of loperamide ingestions: an analysis of 216 poison center reports | journal = Journal of Toxicology. Clinical Toxicology | volume = 35 | issue = 1 | pages = 11–9 | date = 1997 | pmid = 9022646 | doi = 10.3109/15563659709001159 }}</ref> High doses may result in heart problems such as ]s.<ref>{{cite web|title=Safety Alerts for Human Medical Products - Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse|url=https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm|website=U.S. ] (FDA)|access-date=12 June 2016|url-status=live|archive-url=https://web.archive.org/web/20160611093318/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm|archive-date=11 June 2016}}</ref>

===Contraindications===
Treatment should be avoided in the presence of high ] or if the ]. Treatment is not recommended for people who could have negative effects from rebound ]. If suspicion exists of diarrhea associated with organisms that can penetrate the intestinal walls, such as ] or '']'', loperamide is ] as a primary treatment.<ref name=drugs.com/> Loperamide treatment is not used in symptomatic '']'' infections, as it increases the risk of toxin retention and precipitation of toxic megacolon.

Loperamide should be administered with caution to people with ] due to reduced ].<ref>{{ cite web | title = rxlist.com | year = 2005 | url = http://www.rxlist.com/imodium-drug/indications-dosage.htm | url-status = live | archive-url = https://web.archive.org/web/20121127021744/http://www.rxlist.com/imodium-drug/indications-dosage.htm | archive-date = 27 November 2012 | df = dmy-all }}</ref> Additionally, caution should be used when treating people with advanced ], as cases of both viral and bacterial toxic megacolon have been reported. If abdominal distension is noted, therapy with loperamide should be discontinued.<ref name=accessdata.fda.gov>{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory|title=Drugs@FDA: FDA Approved Drug Products|publisher=U.S. ] (FDA)|access-date=14 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160506041852/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory|archive-date=6 May 2016}}</ref>

===Children===
The use of loperamide in children under two years is not recommended. Rare reports of fatal ] associated with ] have been made. Most of these reports occurred in the setting of acute ], overdose, and with very young children less than two years of age.<ref>{{ cite web | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6651 | title = Imodium (Loperamide Hydrochloride) Capsule | work = DailyMed | publisher = NIH | url-status = live | archive-url = https://web.archive.org/web/20100413032222/http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6651 | archive-date = 13 April 2010 | df = dmy-all }}</ref> A review of loperamide in children under 12 years old found that serious adverse events occurred only in children under three years old. The study reported that the use of loperamide should be contraindicated in children who are under 3, systemically ill, malnourished, moderately dehydrated, or have bloody diarrhea.<ref>{{cite journal | vauthors=Li ST, Grossman DC, Cummings P | title = Loperamide therapy for acute diarrhea in children: systematic and meta-analysis | journal = PLOS Medicine | volume = 4 | issue = 3 | date = 2007 | pages = e98 | pmid=17388664 | doi=10.1371/journal.pmed.0040098 | pmc=1831735 | doi-access = free }}</ref>

In 1990, all formulations for children of the antidiarrheal loperamide were banned in Pakistan.<ref>{{ cite web|url=http://www.essentialdrugs.org/edrug/archive/199708/msg00056.php |title=E-DRUG: Chlormezanone |publisher=Essentialdrugs.org |url-status=dead |archive-url=https://web.archive.org/web/20110726035911/http://www.essentialdrugs.org/edrug/archive/199708/msg00056.php |archive-date=26 July 2011 }}</ref>

The ] in the United Kingdom recommends that loperamide should only be given to children under the age of twelve if prescribed by a doctor. Formulations for children are only available on prescription in the UK.<ref>{{cite web |date=20 December 2018 |title=Loperamide: a medicine used to treat diarrhoea |url=https://www.nhs.uk/medicines/loperamide/ |access-date=7 October 2023 |website=] }}</ref>

===Pregnancy and breast feeding===
Loperamide is not recommended in the United Kingdom for use during ] or by ].<ref>{{cite web|url=http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Diarrhoea&medicine=imodium|title=Medicines information links - NHS Choices|access-date=14 May 2016|url-status=dead|archive-url=https://web.archive.org/web/20140110171045/http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Diarrhoea&medicine=imodium|archive-date=10 January 2014}}</ref> Studies in rat models have shown no ]icity, but sufficient studies in humans have not been conducted.<ref>{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo|title=Drugs@FDA: FDA Approved Drug Products|publisher=U.S. ] (FDA) |access-date=14 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160506041852/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo|archive-date=6 May 2016}}</ref> One controlled, prospective study of 89 women exposed to loperamide during their first trimester of pregnancy showed no increased risk of malformations. This, however, was only one study with a small sample size.<ref>{{cite journal | vauthors = Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G | title = Prospective, controlled, multicentre study of loperamide in pregnancy | journal = Canadian Journal of Gastroenterology | volume = 14 | issue = 3 | pages = 185–7 | date = March 2000 | pmid = 10758415 | doi = 10.1155/2000/957649 | doi-access = free }}</ref> Loperamide can be present in breast milk and is not recommended for breastfeeding mothers.<ref name=accessdata.fda.gov/>

==Drug interactions==
Loperamide is a substrate of ]; therefore, the concentration of loperamide increases when given with a P-glycoprotein inhibitor.<ref name=ReferenceA/> Common P-glycoprotein inhibitors include ], ], and ].<ref>{{cite web|url=https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#PgpTransport|title=Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers|publisher=U.S. ] (FDA) |access-date=14 May 2016|url-status=live|archive-url= https://web.archive.org/web/20160510152158/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#PgpTransport|archive-date=10 May 2016}}</ref> Loperamide can decrease the absorption of some other drugs. As an example, ] concentrations can decrease by half when given with loperamide.<ref name=ReferenceA/>

Loperamide is an antidiarrheal agent, which decreases intestinal movement. As such, when combined with other antimotility drugs, the risk of constipation is increased. These drugs include other ]s, ]s, ]s, and ]s.<ref>{{cite web |title=Loperamide Drug Interactions - Epocrates Online |url=https://online.epocrates.com/noFrame/showPage.do?method=drugs&MonographId=44&ActiveSectionId=4 |website=online.epocrates.com |access-date=5 November 2020 |archive-date=1 November 2018 |archive-url=https://web.archive.org/web/20181101070900/https://online.epocrates.com/noFrame/showPage.do?method=drugs&MonographId=44&ActiveSectionId=4 |url-status=live }}</ref>


==Mechanism of action== ==Mechanism of action==
]
Loperamide is an ]-receptor ] and acts on the ] in the ] of the large intestine; by itself it does not affect the ] like other opioids.
Loperamide is an opioid-receptor ] and acts on the ] in the ] of the large intestine. It works like ], decreasing the activity of the myenteric plexus, which decreases the tone of the longitudinal and circular ]s of the intestinal wall.<ref>{{cite web|url=http://www.drugbank.ca/drugs/DB00836|title=DrugBank: Loperamide|access-date=14 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160510135146/http://www.drugbank.ca/drugs/DB00836|archive-date=10 May 2016}}</ref><ref>{{cite web|url=https://www.drugs.com/mmx/loperamide-hydrochloride.html|title=Loperamide Hydrochloride Drug Information, Professional|access-date=14 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160503123442/http://www.drugs.com/mmx/loperamide-hydrochloride.html|archive-date=3 May 2016}}</ref> This increases the time material stays in the intestine, allowing more water to be absorbed from the fecal matter. It also decreases colonic mass movements and suppresses the ].<ref>{{ cite book | vauthors = Katzung BG | title = Basic and Clinical Pharmacology | edition = 9th | year = 2004 | publisher = Lange Medical Books/McGraw Hill | isbn = 978-0-07-141092-2 }}{{Page needed|date=September 2010}}</ref>


Loperamide's circulation in the bloodstream is limited in two ways. Efflux by P-glycoprotein in the intestinal wall reduces the passage of loperamide, and the fraction of drug crossing is then further reduced through ] by the liver.<ref>{{cite book|url=https://books.google.com/books?id=R0W1ErpsQpkC|title=Foye's Principles of Medicinal Chemistry| vauthors = Lemke TL, Williams DA |date=2008|publisher=Lippincott Williams & Wilkins |isbn=9780781768795 |pages = 675 |url-status=live |archive-url= https://web.archive.org/web/20170908145128/https://books.google.com/books?id=R0W1ErpsQpkC |archive-date=8 September 2017 }}</ref><ref>{{cite journal | vauthors = Dufek MB, Knight BM, Bridges AS, Thakker DR | title = P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism | journal = Drug Metabolism and Disposition | volume = 41 | issue = 3 | pages = 642–50 | date = March 2013 | pmid = 23288866 | doi = 10.1124/dmd.112.049965 | df = dmy-all | s2cid = 11014783 }}</ref> Loperamide metabolizes into an ]-like compound, but is unlikely to exert ].<ref>{{cite journal | vauthors = Kalgutkar AS, Nguyen HT | title = Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event | journal = Drug Metabolism and Disposition | volume = 32 | issue = 9 | pages = 943–52 | date = September 2004 | pmid = 15319335 | url = http://dmd.aspetjournals.org/content/32/9/943 | url-status = live | archive-url = https://web.archive.org/web/20170908145128/http://dmd.aspetjournals.org/content/32/9/943 | df = dmy-all | archive-date = 8 September 2017 }}</ref>
It works by decreasing the activity of the ], which, like ], decreases the tone of the longitudinal ]s but increases tone of circular ] of the intestinal wall. This increases the amount of time substances stay in the intestine, allowing for more water to be absorbed out of the fecal matter. Loperamide also decreases colonic mass movements and suppresses the ].<ref>Katzung, Bertram G. ''Basic and Clinical Pharmacology'', 9th ed. (2004). ISBN 0-07-141092-9{{Page needed|date=September 2010}}</ref>


===Blood–brain barrier===
Loperamide molecules do not cross the ] in significant amounts, and, thus, it has no ] or euphoric properties. Any that do cross the blood-brain barrier are quickly exported from the brain by ] (Pgp), also known as multidrug resistance protein (MDR1). Tolerance in response to long-term use has not been reported.
Efflux by P-glycoprotein also prevents circulating loperamide from effectively crossing the blood-brain barrier,<ref>{{cite journal | vauthors = Upton RN | title = Cerebral uptake of drugs in humans | journal = Clinical and Experimental Pharmacology & Physiology | volume = 34 | issue = 8 | pages = 695–701 | date = August 2007 | pmid = 17600543 | doi = 10.1111/j.1440-1681.2007.04649.x | s2cid = 41591261 }}</ref> so it can generally only antagonize muscarinic receptors in the ], and currently has a score of one on the anticholinergic cognitive burden scale.<ref>{{cite web |url=http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf |title=Anticholinergic Cognitive Burden Scale |access-date=23 September 2017 |archive-url=https://web.archive.org/web/20180307142553/http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf |archive-date=7 March 2018 |url-status=dead }}</ref> Concurrent administration of P-glycoprotein inhibitors such as ] potentially allows loperamide to cross the blood-brain barrier and produce central morphine-like effects. At high doses (>70mg), loperamide can saturate P-glycoprotein (thus overcoming the efflux) and produce euphoric effects.<ref>{{cite journal | vauthors = Antoniou T, Juurlink DN | title = Loperamide abuse | journal = CMAJ | volume = 189 | issue = 23 | pages = E803 | date = June 2017 | pmid = 28606977 | pmc = 5468105 | doi = 10.1503/cmaj.161421 }}</ref> Loperamide taken with quinidine was found to produce respiratory depression, indicative of central opioid action.<ref>{{cite journal | vauthors = Sadeque AJ, Wandel C, He H, Shah S, Wood AJ | title = Increased drug delivery to the brain by P-glycoprotein inhibition | journal = Clinical Pharmacology and Therapeutics | volume = 68 | issue = 3 | pages = 231–7 | date = September 2000 | pmid = 11014404 | doi = 10.1067/mcp.2000.109156 | s2cid = 38467170 }}</ref>


However, loperamide has been shown to cause a mild ] during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal have been observed following abrupt discontinuation of long-term therapy with loperamide.<ref>{{Cite journal|author=Yanagita T, Miyasato K, Sato J |title=Dependence potential of loperamide studied in rhesus monkeys |journal=NIDA Research Monograph |volume=27 |issue= |pages=106–13 |year=1979 |pmid=121326}}</ref><ref>{{Cite journal|author=Nakamura H, Ishii K, Yokoyama Y, ''et al.'' |title= |language=Japanese |journal=Yakugaku Zasshi |volume=102 |issue=11 |pages=1074–85 |year=1982 |month=November |pmid=6892112}}</ref> High doses of loperamide have been shown to cause a mild ] during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal were observed following abrupt discontinuation of long-term treatment of animals with loperamide.<ref>{{cite journal | vauthors = Yanagita T, Miyasato K, Sato J | title = Dependence potential of loperamide studied in rhesus monkeys | journal = NIDA Research Monograph | volume = 27 | pages = 106–13 | year = 1979 | pmid = 121326 }}</ref><ref>{{cite journal | vauthors = Nakamura H, Ishii K, Yokoyama Y, Motoyoshi S, Suzuki K, Sekine Y, Hashimoto M, Shimizu M | title = | language = ja | journal = Yakugaku Zasshi | volume = 102 | issue = 11 | pages = 1074–85 | date = November 1982 | pmid = 6892112 | doi = 10.1248/yakushi1947.102.11_1074 | doi-access = free }}</ref>


== Chemistry ==
==Contraindications==
=== Synthesis ===
The use of Loperamide (Imodium) in children under 2 years is not recommended. There have been rare reports of fatal ] associated with ]. Most of these reports occurred in the setting of acute ], overdose, and with very young children less than two years of age.<ref>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6651</ref> In 1990, all
Loperamide is synthesized starting from the ] 3,3-diphenyldihydrofuran-2(3H)-one and ethyl 4-oxopiperidine-1-carboxylate, on a lab scale.<ref name = "Stokbroekx_1973">{{cite journal | vauthors = Stokbroekx RA, Vandenberk J, Van Heertum AH, Van Laar GM, Van der Aa MJ, Van Bever WF, Janssen PA | title = Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides | journal = Journal of Medicinal Chemistry | volume = 16 | issue = 7 | pages = 782–786 | date = July 1973 | pmid = 4725924 | doi = 10.1021/jm00265a009 }}</ref> On a large scale a similar synthesis is followed, except that the lactone and piperidinone are produced from cheaper materials rather than purchased.<ref>{{cite patent | inventor = Janssen PA, Niemegeers CJ | country = US | number = 3714159 | gdate = 1973 }}</ref><ref>{{cite patent | inventor = Janssen PA, Niemegeers CJ | country = US | number = 3884916 | gdate = 1975 }}</ref>
pediatric formulations of the antidiarrheal loperamide (Imodium and others) were banned in ].<ref>http://www.essentialdrugs.org/edrug/archive/199708/msg00056.php</ref>


]
Treatment should be avoided in the presence of ] or if the stool is bloody (]).<ref name="Butler2008">{{Cite journal|author=Butler T |title=Loperamide for the treatment of traveler's diarrhea: broad or narrow usefulness? |journal=Clinical Infectious Diseases |volume=47 |issue=8 |pages=1015–6 |year=2008 |month=October |pmid=18781871 |doi=10.1086/591704}}</ref> It is of no value in diarrhoea caused by ], ] or ].<ref name="Butler2008"/> Treatment is not recommended for patients that could suffer detrimental effects from rebound ]. If there is a suspicion of diarrhea associated with organisms that can penetrate the intestinal walls, such as ] or ], loperamide is ].


== Adverse effects == === Physical properties ===
Loperamide is typically manufactured as the hydrochloride salt. Its main ] has a ] of 224&nbsp;°C and a second polymorph exists with a melting point of 218&nbsp;°C. A ] form has been identified which melts at 190&nbsp;°C.<ref>{{cite journal | vauthors = Van Rompay J, Carter JE | title = Loperamide hydrochloride. | journal = Analytical Profiles of Drug Substances | date = January 1990 | volume = 19 | pages = 341–365 | publisher = Academic Press | veditors = Florey K |doi=10.1016/s0099-5428(08)60372-x| isbn = 9780122608193 }}</ref>
]s (ADRs) associated with Loperamide includes abdominal pain and bloating, nausea, vomiting and constipation. Rare side-effects associated with Loperamide are paralytic ileus, dizziness and rashes.<ref>Australian Medicine Handbook. Bichner F, editor. Adelaide: Australian Medicine Handbook Pty Ltd; 2010.</ref>


=== Hepatic === == History ==
Loperamide hydrochloride was first synthesized in 1969<ref name="Oxford University Press"/> by ] from ] in ], Belgium, following previous discoveries of ] (1956) and ] (1960).<ref>{{cite book|vauthors=Florey K|date=1991|title=Profiles of Drug Substances, Excipients and Related Methodology, Volume 19|url=https://books.google.com/books?id=5ndDXC2L5Q8C&pg=PA342|publisher=Academic Press|isbn=9780080861142|pages=342|access-date=18 May 2016|archive-date=14 January 2023|archive-url=https://web.archive.org/web/20230114195404/https://books.google.com/books?id=5ndDXC2L5Q8C&pg=PA342|url-status=live}}</ref>
It is not recommended for use in hepatic failure since it can precipitate hepatic encephalopathy. <ref>Australian Medicine Handbook. Bichner F, editor. Adelaide: Australian Medicine Handbook Pty Ltd; 2010.</ref>


The first clinical reports on loperamide were published in 1973 in the'' ]''<ref name = "Stokbroekx_1973" /> with the inventor being one of the authors. The trial name for it was "R-18553".<ref>{{cite journal | pmid = 4611432 | volume=24 | issue=10 | title=Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers | year=1974 | journal=Arzneimittelforschung | pages=1653–7 |vauthors=Schuermans V, Van Lommel R, Dom J, Brugmans J }}</ref> ] has a different research code: R-58425.<ref>{{cite web |url=https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2105114 |title=Compound Report Card |access-date=23 June 2016 |url-status=live |archive-url=https://web.archive.org/web/20160811174542/https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2105114 |archive-date=11 August 2016 }}</ref>
===Marketing in Poor nations===


The trial against ] was conducted from December 1972 to February 1974, its results being published in 1977 in the journal ].<ref>{{cite journal | vauthors = Mainguet P, Fiasse R | title = Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection | journal = Gut | volume = 18 | issue = 7 | pages = 575–9 | date = July 1977 | pmid = 326642 | pmc = 1411573 | doi = 10.1136/gut.18.7.575 | df = dmy }}</ref>
In Pakistan, seven infants died in 1989 and 1990 after their parents treated the babies' diarrhea with Imodium, a medicine sold by a subsidiary of Johnson & Johnson.


In 1973, Janssen started to promote loperamide under the brand name Imodium. In December 1976, Imodium got ].<ref>{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=017694&DrugName=IMODIUM&ActiveIngred=LOPERAMIDE%20HYDROCHLORIDE&SponsorApplicant=MCNEIL%20CONS&ProductMktStatus=1&goto=Search.DrugDetails|title=IMODIUM FDA Application No.(NDA) 017694|year=1976|publisher=U.S. ] (FDA)|archive-url=https://web.archive.org/web/20140813131107/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails|archive-date=13 August 2014|url-status=dead|access-date=5 September 2014}}</ref>
Since 1980, the World Health Organization has warned Third World doctors not to use Imodium because it can paralyze a child's intestines. For months a local doctor begged the company to pull the product from stores, but it didn't do so until a British television program broadcast footage of dying babies.<ref>http://community.seattletimes.nwsource.com/archive/?date=19910609&slug=1288069</ref>


During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States.<ref name=court>
==Effectiveness==
{{cite court| litigants=McNeil-PPC, Inc., Plaintiff, v. L. Perrigo Company, and Perrigo Company, Defendants| vol=207| reporter=F. Supp. 2d| opinion=356| court=E.D. Pa.| date=25 June 2002| url=http://law.justia.com/cases/federal/district-courts/FSupp2/207/356/2346092/ <!-- | archive-url=https://www.webcitation.org/6SMyfUhOf?url=http://law.justia.com/cases/federal/district-courts/FSupp2/207/356/2346092/| archive-date=2014-09-05| access-date=2014-09-05 unsupported parameterslast--> }}</ref>
Studies have shown loperamide to be more effective than ], ] or ] for the treatment of acute ]. For the treatment of chronic diarrhea, loperamide was found to be as effective as, or slightly more so than, diphenoxylate.<ref name="urlwww.imodium.com">{{Cite web|url=http://www.imodium.com/images/imodium/pdf/ImodiumLoperimideFacts.pdf |title=www.imodium.com |format= |work= |accessdate=2010-07-27}}</ref>


In March 1988, ] began selling loperamide as an ] under the brand name Imodium A-D.<ref>{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=019487&DrugName=IMODIUM%20A%2DD&ActiveIngred=LOPERAMIDE%20HYDROCHLORIDE&SponsorApplicant=MCNEIL%20CONS&ProductMktStatus=2&goto=Search.DrugDetails|title=IMODIUM A-D FDA Application No.(NDA) 019487|year=1988|publisher=U.S. ] (FDA)|archive-url=https://web.archive.org/web/20140813131107/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails|archive-date=13 August 2014|url-status=dead|access-date=5 September 2014}}</ref>
==Crossing the blood-brain barrier==
Concurrent administration of P-glycoprotein inhibitors such as ] and its other isomer ] (although much higher doses must be used), ]s like ] (Prilosec OTC) and even ] (] as the active ingredient) could potentially allow loperamide to cross the ]. It should however be noted that only quinidine with loperamide was found to produce respiratory depression, indicative of central opioid action.<ref>{{Cite journal|author=Sadeque AJ, Wandel C, He H, Shah S, Wood AJ |title=Increased drug delivery to the brain by P-glycoprotein inhibition |journal=Clinical Pharmacology and Therapeutics |volume=68 |issue=3 |pages=231–7 |year=2000 |month=September |pmid=11014404 |doi=10.1067/mcp.2000.109156}}</ref>


In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but ] voluntarily withdrew it from the market in 1990 after 18 cases of ] (resulting in six deaths) were registered in Pakistan and reported by the ] (WHO).<ref>{{cite journal|url=http://apps.who.int/medicinedocs/index/assoc/h5785e/h5785e.pdf|title=Loperamide: voluntary withdrawal of infant fomulations|year=1990|journal=WHO Drug Information|volume=4|issue=2|pages=73–74|archive-url=https://web.archive.org/web/20140907004301/http://apps.who.int/medicinedocs/index/assoc/h5785e/h5785e.pdf|archive-date=7 September 2014|url-status=dead|access-date=6 September 2014|quote=The leading international supplier of this preparation, Johnson and Johnson, has since informed WHO that having regard to the dangers inherent in improper use and overdosing, this formulation (Imodium Drops), was voluntarily withdrawn from Pakistan in March 1990. The company has since decided not only to withdraw this preparation worldwide but also to remove all syrup formulations from countries where WHO has a programme for the control of diarrhoeal diseases.}}</ref> In the following years (1990-1991), products containing loperamide have been restricted for children's use in several countries (ranging from two to five years of age).<ref>{{cite book|date=2003|title=Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments, 8th Issue|url=https://books.google.com/books?id=leVCukUgNlsC&pg=PA131|publisher=]|isbn=978-92-1-130230-1|pages=130–131|url-status=live|archive-url=https://web.archive.org/web/20170908145128/https://books.google.com/books?id=leVCukUgNlsC&pg=PA131&lpg=PA131&dq=#v=onepage&q&f=true|archive-date=8 September 2017}}</ref>
==See also==

* ] - an anti-flatulent frequently combined with Loperamide in medications
In the late 1980s, before the US patent expired on 30 January 1990,<ref name=court/> McNeil started to develop ] containing ] for treating both ] and ]. In March 1997, the company patented this combination.<ref>{{cite patent|country=US|number=5612054|title=Pharmaceutical compositions for treating gastrointestinal distress|gdate=1997-03-18|fdate=1995-04-19|pridate=1989-11-01|invent1=Jeffrey L. Garwin|assign1=McNeil-PPC, Inc.|status=patent}}</ref> The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet.<ref>{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020606&DrugName=IMODIUM%20MULTI%2DSYMPTOM%20RELIEF&ActiveIngred=LOPERAMIDE%20HYDROCHLORIDE%3B%20SIMETHICONE&SponsorApplicant=MCNEIL&ProductMktStatus=2&goto=Search.DrugDetails|title=IMODIUM MULTI-SYMPTOM RELIEF FDA Application No.(NDA) 020606|year=1997|publisher=U.S. ] (FDA)|archive-url=https://web.archive.org/web/20140813131107/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails|archive-date=13 August 2014|url-status=dead|access-date=5 September 2014}}</ref> A caplet formulation was approved in November 2000.<ref>{{cite web | title=Drug Approval Package: Imodium Advanced (Loperamide HCI and Simethicone NDA #21-140 | website=U.S. ] (FDA) | date=24 December 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-140_Imodium.cfm | access-date=16 December 2020 | archive-date=2 September 2023 | archive-url=https://web.archive.org/web/20230902195525/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-140_Imodium.cfm | url-status=live }}</ref>
* ]

* ]
In November 1993, loperamide was launched as an ] based on ] technology.<ref>{{cite web|url=http://www.thefreelibrary.com/SCHERER+ANNOUNCES+LAUNCH+OF+ANOTHER+PRODUCT+UTILIZING+ITS+ZYDIS...-a014279075|archive-url=https://web.archive.org/web/20140830174558/http://www.thefreelibrary.com/SCHERER+ANNOUNCES+LAUNCH+OF+ANOTHER+PRODUCT+UTILIZING+ITS+ZYDIS...-a014279075|url-status=dead|archive-date=30 August 2014|title=Scherer announces launch of another product utilizing its Zydis technology|date=9 November 1993|publisher=PR Newswire Association LLC|access-date=30 August 2014}}</ref><ref>{{cite book| vauthors = Rathbone MJ, Hadgraft J, Roberts MS |date=2002|title=Modified-Release Drug Delivery Technology|chapter=The Zydis Oral Fast-Dissolving Dosage Form|chapter-url=https://books.google.com/books?id=mw9W82MLYZ8C&q=%20janssen&pg=PA200 |publisher=CRC Press|pages = |isbn=9780824708696|access-date=26 August 2014|url-access=registration|url=https://archive.org/details/modifiedreleased00mich/page/200}}</ref>
* ] - an Mu opioid antagonist (in contrast to Loperamide as an Mu opioid agonist) that doesn't cross the blood brain barrier so as to not affect CNS

In 2013, loperamide in the form of 2-mg tablets was added to the ].<ref>{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO model list of essential medicines and the 4th WHO model list of essential medicines for children) | year = 2014 | publisher = World Health Organization | location = Geneva | author-link = World Health Organization | hdl = 10665/112729 | id = WHO technical report series;985 | hdl-access=free | isbn = 9789241209854 | issn = 0512-3054 }}</ref>

In 2020, it was discovered by researchers at ] that Loperamide was effective at killing ] cells.<ref>{{cite web |url=https://aktuelles.uni-frankfurt.de/englisch/anti-diarrhoea-drug-drives-cancer-cells-to-cell-death/ |title=Anti-diarrhoea drug drives cancer cells to cell death – Aktuelles aus der Goethe-Universität Frankfurt |website=aktuelles.uni-frankfurt.de |url-status=dead |archive-url=https://web.archive.org/web/20201223113316/https://aktuelles.uni-frankfurt.de/englisch/anti-diarrhoea-drug-drives-cancer-cells-to-cell-death/ |archive-date=23 December 2020}}</ref>

==Society and culture==
===Legal status===
==== United States ====
Loperamide was formerly a ] in the United States. First, it was a ] controlled substance. However, this was lowered to ]. Loperamide was finally removed from control by the ] in 1982, courtesy of then-] ]<ref>{{cite web | vauthors = Mullen F |date=3 November 1982 |title=FR Doc. 82-30264 |url=https://archives.federalregister.gov/issue_slice/1982/11/3/49841-49843.pdf |archive-url=https://archive.today/20230627043028/https://archives.federalregister.gov/issue_slice/1982/11/3/49841-49843.pdf |archive-date=27 June 2023 |access-date=26 June 2023 |website=] |publisher=]}}</ref>

====UK====
Loperamide can be sold freely to the public by chemists (pharmacies) as the treatment of diarrhoea and acute diarrhoea associated with medically diagnosed irritable bowel syndrome in adults over 18 years of age<ref>{{cite web | url=https://bnf.nice.org.uk/drugs/loperamide-hydrochloride/#:~:text=Loperamide%20can%20be%20sold%20to%20the%20public%2C%20provided,doctor%29%20in%20adults%20over%2018%20years%20of%20age | title=BNF is only available in the UK }}</ref>

===Economics===
Loperamide is sold as a ].<ref name=AHFS2015/><ref name=Ric2013/> In 2016, Imodium was one of the biggest-selling branded over-the-counter medications sold in Great Britain, with sales of £32.7 million.<ref>{{cite journal | title=A breakdown of the over-the-counter medicines market in Britain in 2016 | journal=The Pharmaceutical Journal | publisher=Royal Pharmaceutical Society | vauthors=Connelly D | date=April 2017 | issn=2053-6186 | doi=10.1211/pj.2017.20202662 | volume=298 | issue=7900 }}</ref>

===Brand names===
Loperamide was originally marketed as Imodium, and many generic brands are sold.<ref name=Names/>

===Off-label/unapproved use===
Loperamide has typically been deemed to have a relatively low risk of misuse.<ref>{{cite journal | vauthors = Baker DE | title = Loperamide: a pharmacological review | journal = Reviews in Gastroenterological Disorders | volume = 7 | issue = Suppl 3 | pages = S11-8 | date = 2007 | pmid = 18192961 }}</ref> In 2012, no reports of loperamide abuse were made.<ref name=Springer2012>{{cite book|title=Mediators and Drugs in Gastrointestinal Motility II: Endogenous and Exogenous Agents|url=https://books.google.com/books?id=d-TrCAAAQBAJ&pg=PA290|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-68474-6|pages=290–|access-date=18 May 2016|archive-date=12 January 2023|archive-url=https://web.archive.org/web/20230112234947/https://books.google.com/books?id=d-TrCAAAQBAJ&pg=PA290|url-status=live}}</ref> In 2015, however, case reports of extremely high-dose loperamide use were published.<ref name=MacDonaldHeiner2015>{{cite journal | vauthors = MacDonald R, Heiner J, Villarreal J, Strote J | title = Loperamide dependence and abuse | journal = BMJ Case Reports | volume = 2015 | pages = bcr2015209705 | date = May 2015 | pmid = 25935922 | pmc = 4434293 | doi = 10.1136/bcr-2015-209705 }}</ref><ref name=DierksenGonsoulin2015>{{cite journal | vauthors = Dierksen J, Gonsoulin M, Walterscheid JP | title = Poor Man's Methadone: A Case Report of Loperamide Toxicity | journal = The American Journal of Forensic Medicine and Pathology | volume = 36 | issue = 4 | pages = 268–70 | date = December 2015 | pmid = 26355852 | doi = 10.1097/PAF.0000000000000201 | s2cid = 19635919 }}</ref> The primary intent of users has been to manage symptoms of opioid withdrawal such as diarrhea, although a small portion derive psychoactive effects at these higher doses.<ref name=Stan2017/> At these higher doses central nervous system penetration occurs and long-term use may lead to tolerance, dependence, and withdrawal on abrupt cessation.<ref name=Stan2017>{{cite journal | vauthors = Stanciu CN, Gnanasegaram SA | title = Loperamide, the "Poor Man's Methadone": Brief Review | journal = Journal of Psychoactive Drugs | volume = 49 | issue = 1 | pages = 18–21 | date = 2017 | pmid = 27918873 | doi = 10.1080/02791072.2016.1260188 | s2cid = 31713818 }}</ref> Dubbing it "the poor man's ]", clinicians warned that increased restrictions on the availability of prescription opioids passed in response to the ] were prompting recreational users to turn to loperamide as an over-the-counter treatment for withdrawal symptoms.<ref>{{cite news|url=https://www.washingtonpost.com/news/morning-mix/wp/2016/05/04/physicians-alarmed-by-abuse-of-over-the-counter-diarrhea-medicine-you-know-well/|title=Abuse of diarrhea medicine you know well is alarming physicians|vauthors=Guarino B|date=4 May 2016|newspaper=Washington Post|access-date=6 May 2016|archive-date=6 May 2016|archive-url=https://web.archive.org/web/20160506050851/https://www.washingtonpost.com/news/morning-mix/wp/2016/05/04/physicians-alarmed-by-abuse-of-over-the-counter-diarrhea-medicine-you-know-well/|url-status=live}}</ref> The FDA responded to these warnings by calling on drug manufacturers to voluntarily limit the package size of loperamide for public-safety reasons.<ref>{{cite news|url=https://www.washingtonpost.com/news/to-your-health/wp/2018/01/30/fda-wants-to-curb-abuse-of-imodium-the-poor-mans-methadone/|title=FDA wants to curb abuse of Imodium, 'the poor man's methadone'|vauthors=McGinley L|date=30 January 2018|newspaper=Washington Post|access-date=30 January 2018|issn=0190-8286|archive-date=30 January 2018|archive-url=https://web.archive.org/web/20180130194140/https://www.washingtonpost.com/news/to-your-health/wp/2018/01/30/fda-wants-to-curb-abuse-of-imodium-the-poor-mans-methadone/|url-status=live}}</ref><ref name=FDA2018>{{cite web|author=Office of the Commissioner|title=Safety Alerts for Human Medical Products - Imodium (loperamide) for Over-the-Counter Use: Drug Safety Communication - FDA Limits Packaging To Encourage Safe Use|url=https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm|website=U.S. ] (FDA)|access-date=2 February 2018|archive-date=8 April 2018|archive-url=https://web.archive.org/web/20180408052631/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm|url-status=live}}</ref> However, there is no quantity restriction on number of packages that can be purchased, and most pharmacies do not feel capable of restricting its sale, so it is unclear that this intervention will have any impact without further regulation to place loperamide behind the counter.<ref name="Feldman_2020">{{cite journal | vauthors = Feldman R, Everton E | title = National assessment of pharmacist awareness of loperamide abuse and ability to restrict sale if abuse is suspected | journal = Journal of the American Pharmacists Association | volume = 60 | issue = 6 | pages = 868–873 | date = November 2020 | pmid = 32641253 | doi = 10.1016/j.japh.2020.05.021 | s2cid = 220436708 }}</ref> Since 2015, several reports of sometimes-fatal ] due to high-dose loperamide abuse have been published.<ref>{{cite journal | vauthors = Eggleston W, Clark KH, Marraffa JM | title = Loperamide Abuse Associated With Cardiac Dysrhythmia and Death | journal = Annals of Emergency Medicine | volume = 69 | issue = 1 | pages = 83–86 | date = January 2017 | pmid = 27140747 | doi = 10.1016/j.annemergmed.2016.03.047 }}</ref><ref name="MukarramHindi2016">{{cite journal | vauthors = Mukarram O, Hindi Y, Catalasan G, Ward J | title = Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature | journal = Case Reports in Medicine | volume = 2016 | pages = 4061980 | year = 2016 | pmid = 26989420 | pmc = 4775784 | doi = 10.1155/2016/4061980 | doi-access = free }}</ref>


==References== ==References==
{{Reflist}} {{Reflist}}

==External links==
*


{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} {{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{Opioid receptor modulators}}
{{Portal bar | Medicine}}
{{Authority control}}


]
] ]
] ]
] ]
] ]
]
]
]
]
]
]
] ]
] ]
] ]

]
]
]
]
]
]
]
]
]
]
]
]
]
]